Brae­burn Phar­ma files for $150M IPO; Tiziana in-li­cens­es Novim­mune an­ti­body

• Brae­burn Phar­ma­ceu­ti­cals, which mar­kets and de­vel­ops treat­ments for opi­oid ad­dic­tion, has filed for a $150 mil­lion IPO. The of­fer­ing notes that Ap­ple Tree Part­ners has agreed to buy $40 mil­lion in stock. Here’s the S-1.

• The UK’s Tiziana Life Sci­ences has bagged a glob­al li­cense for the IL-6R an­ti­body NI-1201 from Novim­mune. The com­pa­nies did not spell out the fi­nan­cial terms of the deal. “We view NI-1201 as a po­ten­tial game-chang­er for ad­dress­ing the high un­met need of au­toim­mune and in­flam­ma­to­ry dis­eases” com­ment­ed Gabriele Cer­rone, Chair­man of Tiziana Life Sci­ences. “The ac­qui­si­tion of NI-1201 not on­ly strength­ens our busi­ness strat­e­gy of de­vel­op­ing nov­el ful­ly hu­man mAbs to treat life-threat­en­ing in­flam­ma­to­ry dis­eases such as non-al­co­holic steato­hep­ati­tis (NASH) and rheuma­toid arthri­tis, but ex­pands our po­ten­tial to lever­age the pi­o­neer­ing work we are do­ing with foralum­ab, the oral an­ti-CD3 mAb to treat au­toim­mune and in­flam­ma­to­ry dis­eases.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER